Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00104468
Status:
TERMINATED
Last Update Posted:
2008-01-17
First Post:
2005-02-28
Brief Title:
Study of Troxatyl Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia AML
Sponsor:
SGX Pharmaceuticals Inc
Organization:
SGX Pharmaceuticals Inc
Study Overview
Official Title:
An Open-Label Single-Arm Multi-Center Phase I Study of Troxatyl Troxacitabine Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia
Status:
TERMINATED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Trial stopped June 2007
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I single-arm open-label multi-center study of rising doses of Troxatyl whose purpose is to determine the safety tolerance and pharmacokinetics and to establish the recommended infusion schedule of Troxatyl
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None